New generic diabetes drug is trouble waiting to happen
Millions of diabetics are about to take a huge gamble, a roll of the dice that could end in death by a particularly horrible disease.
You'd think the FDA would be trying to protect them from that risk -- but they're the ones rolling the dice, signing off on a generic version of the diabetes drug Actos to make it available to millions of new patients.
Many of them will make the switch simply because it's newer -- and newer drugs are better, right?
Wrong. In this case, dead wrong -- because Actos users have a much higher risk of bladder cancer, a cancer so deadly it kills half the patients who get it within five years.
The shock of it is that the feds are completely aware of the dangers. They read the same studies I do -- like the one that recently found that Actos users are 83 percent more likely get bladder cancer.
That's overall, by the way. The more you take, the higher the risk -- eventually skyrocketing to 2.5 times in patients who take the highest cumulative dose.
It just makes no sense to make Actos available to more people, especially when you consider how dangerous the drug is even without those links to bladder cancer.
Remember Avandia, the diabetes drug in the same class that was pulled from the market for its risk of death by heart attack and heart failure? Well, some studies have found that Actos packs some very similar heart risks.
Yet Avandia is gone and Actos is not only still here, but about to go generic.
If you're diabetic yourself, I know how tough it can be. I know you feel like you have to constantly choose between a bad treatment and one that's even worse.
But you don't have to make that choice anymore.
You CAN beat this disease and reduce or even eliminate your drugs completely, and I can help make it happen.